Tag - PTIX

Maxim Group initiated coverage of Protagenic Therapeutics (NASDAQ:PTIX) with a “buy” rating and price target of $4. The stock closed at $1.80 on Oct. 28. Protagenic is developing its lead asset, PT00114, for the...